Support program for patients with gastroesophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to evaluate the effectiveness of the STRONG intervention, which includes dietitian consultations and remote monitoring, in reducing malnutrition among patients with gastroesophageal cancer compared to standard care. Participants will receive personalized nutrition guidance and support while undergoing chemotherapy and/or radiation therapy. The study will also collect data on social determinants of health to better understand the needs of these patients. The intervention is designed to enhance nutritional status and overall well-being during treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must be 18 years of age or older
* Participants must have locally advanced or metastatic gastroesophageal cancer (GEC)
* Participants must plan to initiate chemotherapy and/or radiation therapy with a plan to have surgery or definitive treatment follow up at Moffitt
* Participants must be able to speak and read Spanish and/or English
* Participants must be able to provide informed consent

Exclusion Criteria:

* Participants have a documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g. severe dementia)
* Use of feeding tubes at the time of study enrollment

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• UNC Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Amir Alishahi Tabriz, MD, PhD, MPH — Moffitt Cancer Center
• Study coordinator: Emma Hume
• Email: Emma.Hume@moffitt.org
• Phone: 813-745-6426

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer

  A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.

  Recruiting at 3 sites Phase 1 Dong-A ST Co., Ltd. · Seongnam, Bundang and 2 other locations · NCT07481357

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Pulsed low-dose-rate radiation plus chemotherapy versus standard chemoradiation for esophageal cancer

  This trial will test whether delivering radiation as pulsed low-dose-rate together with chemotherapy reduces serious esophagitis compared with standard chemoradiation in adults with locally advanced esophageal adenocarcinoma.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06906887

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• Combining PD-1 antibody and chemotherapy followed by surgery for limited metastatic gastric cancer

  This study tests if combining immunotherapy and chemotherapy with surgery can help people with limited metastatic gastric cancer live longer and feel better compared to just using the treatments without surgery.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai City and 1 other locations · NCT06468280

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.